A5063674578- Lymphoma Diagnosis and Treatment
- Musculoskeletal Disorders and Rehabilitation
- Viral-associated cancers and disorders
- Educational Technology in Learning
- Sarcoma Diagnosis and Treatment
- Healthcare Systems and Technology
- Web and Library Services
- Medical Research and Practices
- Medical Coding and Health Information
- Online and Blended Learning
- Global Peace and Security Dynamics
- CAR-T cell therapy research
- Open Education and E-Learning
- Dental Education, Practice, Research
- CNS Lymphoma Diagnosis and Treatment
- Historical Medical Research and Treatments
- Pharmaceutical Practices and Patient Outcomes
- Library Science and Information Systems
Fiona Stanley Hospital
2023-2024
Sir Charles Gairdner Hospital
2019-2024
Follicular lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, Group d’Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high FL patients harmonize clinical trial populations. The utilization of GELF (GELFc) in routine therapeutic decision- making poorly described. This multicenter retrospective study evaluated patterns GELFc at presentation decision-making newly diagnosed, advanced-stage...
Abstract Polatuzumab vedotin (Pola) is an approved therapy in combination with rituximab and bendamustine for relapsed or refractory diffuse large B‐cell lymphoma (RR‐DLBCL) based on positive results of the landmark phase II randomised G029365 trial. However, trial many novel therapies RR‐DLBCL have not been replicated routine care cohorts, as patient populations are heterogeneous eligibility increasingly restrictive. We evaluated outcomes from pola ± patients enrolled a compassionate access...
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: RRDLBCL outcomes remain poor despite autologous transplant and CAR-T therapies offering potential cure to a minority. Evidence for current is mostly from phase II trials with stringent eligibility criteria. Applicability real-world populations poorly understood. PolaBR efficacy in RR DLBCL was shown the landmark GO29365 study (BCT02600897; Sehn Blood Adv 2022). However, of routine care patients (pts) who fail meet original...